Erika Krick

1.4k total citations
28 papers, 708 citations indexed

About

Erika Krick is a scholar working on Pulmonary and Respiratory Medicine, Small Animals and Genetics. According to data from OpenAlex, Erika Krick has authored 28 papers receiving a total of 708 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 12 papers in Small Animals and 11 papers in Genetics. Recurrent topics in Erika Krick's work include Veterinary Oncology Research (24 papers), Virus-based gene therapy research (11 papers) and Infectious Diseases and Mycology (10 papers). Erika Krick is often cited by papers focused on Veterinary Oncology Research (24 papers), Virus-based gene therapy research (11 papers) and Infectious Diseases and Mycology (10 papers). Erika Krick collaborates with scholars based in United States, Canada and Argentina. Erika Krick's co-authors include Karin U. Sørenmo, Frances S. Shofer, Beth Overley, Dorothy Cimino Brown, Shun Watanabe, Craig A. Clifford, Thomas P. Gregor, Nicola J. Mason, Rachel Cohen and Katherine A. Skorupski and has published in prestigious journals such as PLoS ONE, Journal of the American Veterinary Medical Association and Journal of Veterinary Internal Medicine.

In The Last Decade

Erika Krick

26 papers receiving 668 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erika Krick United States 15 538 322 218 119 94 28 708
Davide Berlato United Kingdom 14 516 1.0× 378 1.2× 91 0.4× 83 0.7× 109 1.2× 31 623
Giorgio Romanelli Italy 14 470 0.9× 262 0.8× 132 0.6× 60 0.5× 54 0.6× 35 602
Kaitlin M. Curran United States 13 398 0.7× 188 0.6× 147 0.7× 67 0.6× 58 0.6× 37 524
Sarah C. Charney United States 17 506 0.9× 204 0.6× 169 0.8× 183 1.5× 87 0.9× 22 824
Paola Laganga Italy 11 318 0.6× 162 0.5× 109 0.5× 57 0.5× 46 0.5× 18 399
Beth Overley United States 13 433 0.8× 190 0.6× 223 1.0× 88 0.7× 19 0.2× 13 589
Sara D. Allstadt United States 12 319 0.6× 150 0.5× 174 0.8× 42 0.4× 44 0.5× 18 411
Stephen J. Engler United States 10 422 0.8× 233 0.7× 178 0.8× 90 0.8× 46 0.5× 10 519
Andrea B. Flory United States 12 397 0.7× 248 0.8× 162 0.7× 54 0.5× 40 0.4× 20 438
Matthew J. Atherton United States 14 314 0.6× 127 0.4× 285 1.3× 194 1.6× 49 0.5× 35 685

Countries citing papers authored by Erika Krick

Since Specialization
Citations

This map shows the geographic impact of Erika Krick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erika Krick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erika Krick more than expected).

Fields of papers citing papers by Erika Krick

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erika Krick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erika Krick. The network helps show where Erika Krick may publish in the future.

Co-authorship network of co-authors of Erika Krick

This figure shows the co-authorship network connecting the top 25 collaborators of Erika Krick. A scholar is included among the top collaborators of Erika Krick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erika Krick. Erika Krick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Sørenmo, Karin U., Erika Krick, Nicole M. Weinstein, et al.. (2021). Response‐based modification of CHOP chemotherapy for canine B‐cell lymphoma. Veterinary and Comparative Oncology. 19(3). 541–550. 6 indexed citations
3.
Willcox, Jennifer L., Carlos Henrique de Mello Souza, Brian D. Husbands, et al.. (2021). Outcome in dogs with curative‐intent treatment of localized primary pulmonary histiocytic sarcoma. Veterinary and Comparative Oncology. 20(2). 458–464.
4.
5.
Mauldin, Glenna E., et al.. (2019). Efficacy and toxicity of mustargen, vincristine, procarbazine and prednisone (MOPP) for the treatment of relapsed or resistant lymphoma in cats. Journal of Feline Medicine and Surgery. 22(4). 299–304. 2 indexed citations
6.
Skorupski, Katherine A., et al.. (2017). Outcome following treatment of feline gastrointestinal mast cell tumours. Veterinary and Comparative Oncology. 16(2). 188–193. 9 indexed citations
7.
Krick, Erika, Matti Kiupel, Amy C. Durham, et al.. (2017). Investigating Associations Between Proliferation Indices, C-kit, and Lymph Node Stage in Canine Mast Cell Tumors. Journal of the American Animal Hospital Association. 53(5). 258–264. 8 indexed citations
8.
Krick, Erika, et al.. (2016). Febrile neutropenia in cats treated with chemotherapy. Veterinary and Comparative Oncology. 15(2). 550–556. 5 indexed citations
9.
Culp, William T. N., Chick Weisse, Allyson Berent, et al.. (2015). Early Tumor Response to Intraarterial or Intravenous Administration of Carboplatin to Treat Naturally Occurring Lower Urinary Tract Carcinoma in Dogs. Journal of Veterinary Internal Medicine. 29(3). 900–907. 13 indexed citations
10.
Brown, Dorothy Cimino, et al.. (2015). Palliative radiation therapy for solid tumors in dogs: 103 cases (2007–2011). Journal of the American Veterinary Medical Association. 248(1). 72–82. 15 indexed citations
11.
McNeill, Conor J., et al.. (2015). Outcome and toxicity assessment of feline small cell lymphoma: 56 cases (2000–2010). Veterinary Medicine and Science. 1(2). 51–62. 22 indexed citations
12.
Giuffrida, Michelle A., et al.. (2015). Efficacy and toxicity of carboplatin and cytarabine chemotherapy for dogs with relapsed or refractory lymphoma (2000–2013). Veterinary and Comparative Oncology. 15(2). 400–410. 13 indexed citations
13.
Patel, Reema, Albert S. Baldwin, Michael J. May, et al.. (2014). A Phase I Clinical Trial of Systemically Delivered NEMO Binding Domain Peptide in Dogs with Spontaneous Activated B-Cell like Diffuse Large B-Cell Lymphoma. PLoS ONE. 9(5). e95404–e95404. 35 indexed citations
14.
Jackson, Karen V., et al.. (2013). Lymphoma in cats treated with a weekly cyclophosphamide-, vincristine-, and prednisone-based protocol: 114 cases (1998–2008). Journal of the American Veterinary Medical Association. 242(8). 1104–1109. 30 indexed citations
15.
Donnelly, Lane F., Christine Mullin, Ján Balko, et al.. (2013). Evaluation of histological grade and histologically tumour‐free margins as predictors of local recurrence in completely excised canine mast cell tumours. Veterinary and Comparative Oncology. 13(1). 70–76. 63 indexed citations
16.
Krick, Erika, et al.. (2012). Prospective Clinical Trial to Compare Vincristine and Vinblastine in a COP-Based Protocol for Lymphoma in Cats. Journal of Veterinary Internal Medicine. 27(1). 134–140. 27 indexed citations
17.
Krick, Erika, Karin U. Sørenmo, Shelley C. Rankin, et al.. (2011). Evaluation of Clostridium novyi–NT spores in dogs with naturally occurring tumors. American Journal of Veterinary Research. 73(1). 112–118. 54 indexed citations
18.
Sørenmo, Karin U., et al.. (2010). Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases. Veterinary and Comparative Oncology. 8(3). no–no. 71 indexed citations
19.
Skorupski, Katherine A., Carlos O. Rodriguez, Erika Krick, et al.. (2009). Long‐term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy*. Veterinary and Comparative Oncology. 7(2). 139–144. 47 indexed citations
20.
Krick, Erika, et al.. (2009). Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival*. Veterinary and Comparative Oncology. 7(2). 130–138. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Davide Berlato Breakdown of academic impact, for papers by Giorgio Romanelli Breakdown of academic impact, for papers by Kaitlin M. Curran Breakdown of academic impact, for papers by Sarah C. Charney Breakdown of academic impact, for papers by Paola Laganga Breakdown of academic impact, for papers by Beth Overley Breakdown of academic impact, for papers by Sara D. Allstadt Breakdown of academic impact, for papers by Stephen J. Engler Breakdown of academic impact, for papers by Andrea B. Flory Breakdown of academic impact, for papers by Matthew J. Atherton
Rankless by CCL
2026